Measuring the Individual Benefit of a Medical or Behavioral Treatment Using Generalized Linear Mixed-effects Models

Overview

Journal Stat Med

Publisher Wiley

Specialty Public Health

Date 2016 Jun 22

PMID 27323698

Citations 9

Authors

Francisco J Diaz

Affiliations

Soon will be listed here.

Abstract

We propose statistical definitions of the individual benefit of a medical or behavioral treatment and of the severity of a chronic illness. These definitions are used to develop a graphical method that can be used by statisticians and clinicians in the data analysis of clinical trials from the perspective of personalized medicine. The method focuses on assessing and comparing individual effects of treatments rather than average effects and can be used with continuous and discrete responses, including dichotomous and count responses. The method is based on new developments in generalized linear mixed-effects models, which are introduced in this article. To illustrate, analyses of data from the Sequenced Treatment Alternatives to Relieve Depression clinical trial of sequences of treatments for depression and data from a clinical trial of respiratory treatments are presented. The estimation of individual benefits is also explained. Copyright © 2016 John Wiley & Sons, Ltd.

Citing Articles

Active Ingredients of Voice Therapy for Muscle Tension Voice Disorders: A Retrospective Data Audit.

Madill C, Chacon A, Kirby E, Novakovic D, Nguyen D J Clin Med. 2021; 10(18).

PMID: 34575246 PMC: 8469541. DOI: 10.3390/jcm10184135.

Using population crossover trials to improve the decision process regarding treatment individualization in N-of-1 trials.

Diaz F Stat Med. 2021; 40(20):4345-4361.

PMID: 34213011 PMC: 10773237. DOI: 10.1002/sim.9030.

Improvement in the long-term care burden after surgical treatment of patients with idiopathic normal pressure hydrocephalus: a supplementary study.

Ishikawa M, Yamada S, Miyajima M, Kazui H, Mori E Sci Rep. 2021; 11(1):11732.

PMID: 34083550 PMC: 8175749. DOI: 10.1038/s41598-021-90911-2.

A graphical approach to assess the goodness-of-fit of random-effects linear models when the goal is to measure individual benefits of medical treatments in severely ill patients.

Wang Z, Diaz F BMC Med Res Methodol. 2020; 20(1):193.

PMID: 32689939 PMC: 7370523. DOI: 10.1186/s12874-020-01054-3.

Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users.

Zhang X, De Leon J, Crespo-Facorro B, Diaz F J Biopharm Stat. 2020; 30(5):916-940.

PMID: 32511941 PMC: 9030227. DOI: 10.1080/10543406.2020.1765371.

References

Sharp S, Thompson S, Altman D . The relation between treatment benefit and underlying risk in meta-analysis. BMJ. 1996; 313(7059):735-8. PMC: 2352108. DOI: 10.1136/bmj.313.7059.735. View

Whiting B, Kelman A, Grevel J . Population pharmacokinetics. Theory and clinical application. Clin Pharmacokinet. 1986; 11(5):387-401. DOI: 10.2165/00003088-198611050-00004. View

Diaz F, Berg M, Krebill R, Welty T, Gidal B, Alloway R . Random-effects linear modeling and sample size tables for two special crossover designs of average bioequivalence studies: the four-period, two-sequence, two-formulation and six-period, three-sequence, three-formulation designs. Clin Pharmacokinet. 2013; 52(12):1033-43. DOI: 10.1007/s40262-013-0103-4. View

Diaz F, Eap C, Ansermot N, Crettol S, Spina E, De Leon J . Can valproic acid be an inducer of clozapine metabolism?. Pharmacopsychiatry. 2014; 47(3):89-96. PMC: 4229130. DOI: 10.1055/s-0034-1371866. View

Senn S . Mastering variation: variance components and personalised medicine. Stat Med. 2015; 35(7):966-77. PMC: 5054923. DOI: 10.1002/sim.6739. View

Li W, Girard P, Boissel J, Gueyffier F . The calculation of a confidence interval on the absolute estimated benefit for an individual patient. Comput Biomed Res. 1998; 31(4):244-56. DOI: 10.1006/cbmr.1998.1477. View

Diaz F, Cogollo M, Spina E, Santoro V, Rendon D, De Leon J . Drug dosage individualization based on a random-effects linear model. J Biopharm Stat. 2012; 22(3):463-84. DOI: 10.1080/10543406.2010.547264. View

Labbe K, Detsky A, ORourke K . Meta-analysis in clinical research. Ann Intern Med. 1987; 107(2):224-33. DOI: 10.7326/0003-4819-107-2-224. View

Sheiner L, Rosenberg B, Melmon K . Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972; 5(5):411-59. DOI: 10.1016/0010-4809(72)90051-1. View

10.

Fava M, Rush A, Trivedi M, Nierenberg A, Thase M, Sackeim H . Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003; 26(2):457-94, x. DOI: 10.1016/s0193-953x(02)00107-7. View

11.

Botts S, Diaz F, Santoro V, Spina E, Muscatello M, Cogollo M . Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6):1453-8. DOI: 10.1016/j.pnpbp.2008.04.018. View

12.

Diaz F, Rivera T, Josiassen R, De Leon J . Individualizing drug dosage by using a random intercept linear model. Stat Med. 2006; 26(9):2052-73. DOI: 10.1002/sim.2636. View

13.

Diaz F, Yeh H, De Leon J . Role of Statistical Random-Effects Linear Models in Personalized Medicine. Curr Pharmacogenomics Person Med. 2013; 10(1):22-32. PMC: 3580802. DOI: 10.2174/1875692111201010022. View

14.

Lubsen J, Tijssen J . Large trials with simple protocols: indications and contraindications. Control Clin Trials. 1989; 10(4 Suppl):151S-160S. DOI: 10.1016/0197-2456(89)90054-8. View

15.

Boissel J, Kahoul R, Marin D, Boissel F . Effect model law: an approach for the implementation of personalized medicine. J Pers Med. 2015; 3(3):177-90. PMC: 4251395. DOI: 10.3390/jpm3030177. View

16.

KALOW W, Endrenyi L, Tang B . Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Pharmacology. 1999; 58(6):281-4. DOI: 10.1159/000028292. View

17.

Diaz F, De Leon J . The mathematics of drug dose individualization should be built with random-effects linear models. Ther Drug Monit. 2013; 35(2):276-7. DOI: 10.1097/FTD.0b013e318283e3c6. View

18.

Pillai G, Mentre F, Steimer J . Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn. 2005; 32(2):161-83. DOI: 10.1007/s10928-005-0062-y. View

19.

Schall R, Endrenyi L, Ring A . Residuals and outliers in replicate design crossover studies. J Biopharm Stat. 2010; 20(4):835-49. DOI: 10.1080/10543401003618876. View